SCHEMBL11968634

SCHEMBL11968634

CN(C)C(=O)C(O)c1cncc(-c2cnc3[nH]cc(-c4ccc(C(N)=O)cc4)c3c2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K11 Q16584 7/20 0.59
CAMKK2 Q96RR4 5/20 0.55
AXL P30530 3/20 0.53
ABL1 P00519 2/20 0.53
DYRK1A Q13627 2/20 0.53
GSK3B P49841 2/20 0.53
CDC7 O00311 1/20 0.53
PLK4 O00444 1/20 0.53
CHEK1 O14757 1/20 0.53
AURKA O14965 1/20 0.53
MAPK13 O15264 1/20 0.53
PDPK1 O15530 1/20 0.53
DYRK3 O43781 1/20 0.53
ROCK2 O75116 1/20 0.53
RPS6KA5 O75582 1/20 0.53
PRKD3 O94806 1/20 0.53
PAK4 O96013 1/20 0.53
CHEK2 O96017 1/20 0.53
EGFR P00533 1/20 0.53
NTRK1 P04629 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14041541 0.90 NTRK1 (0.55) MAP3K11CAMKK2AXLABL1DYRK1A
SCHEMBL11968617 0.89 MAP3K11 (0.52) MAP3K11CAMKK2AXLABL1DYRK1A
SCHEMBL11968615 0.89 MAP3K11 (0.51) MAP3K11CAMKK2AXLABL1DYRK1A
SCHEMBL11968633 0.89 MAPK8 (0.54) MAP3K11CAMKK2AXLABL1DYRK1A
SCHEMBL11968626 0.89 CLK1 (0.53) MAP3K11CAMKK2AXLABL1DYRK1A
SCHEMBL11968623 0.88 SGK1 (0.56) MAP3K11CAMKK2AXLABL1DYRK1A
SCHEMBL11968628 0.88 NTRK1 (0.56) MAP3K11AXLABL1NTRK1
SCHEMBL11968629 0.88 MAP3K11 (0.50) MAP3K11CAMKK2AXLABL1DYRK1A
SCHEMBL11968618 0.87 DYRK1A (0.55) MAP3K11CAMKK2AXLABL1DYRK1A
SCHEMBL11968621 0.86 NEK1 (0.53) MAP3K11CAMKK2AXLABL1DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242280-B2 morpholin-4-yl-{3-[3-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl-phenyl}-methanone; FMS-like tyrosine kinase 3 (FLT3), is implicated in cancers, including leukemia, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia SGX PHARMACEUTICALS, INC. (US) 2012-08-14 US disclosed
US-8242280-B2 morpholin-4-yl-{3-[3-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl-phenyl}-methanone; FMS-like tyrosine kinase 3 (FLT3), is implicated in cancers, including leukemia, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia SGX PHARMACEUTICALS, INC. (US) 2012-08-14 US disclosed
US-20080261921-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-23 US disclosed
US-20080261921-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-23 US disclosed
WO-2008124848-A1 FUSED RING HETEROCYCLE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261921-A1 FUSED RING HETEROCYCLE KINASE MODULATORS MAP3K20, MAP3K19, MAP4K2 MAP3K11 18/4885CAMKK2 82/4885AXL 711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.